GO
Loading...

Abbott Laboratories

More

  • Merck "Adapts" To Tredaptive Setback Tuesday, 29 Apr 2008 | 11:37 AM ET

    Investors are finding no solace in Merck's reaffirmation that it'll still hit its earnings numbers this year. Instead they're punishing the stock after the company announced what everyone is calling a surprise and a significant setback.

  • Merck Shares Plunge as Cholesterol Drug Rejected Tuesday, 29 Apr 2008 | 11:20 AM ET
    Merck

    U.S. health regulators have rejected a new drug from Merck that was designed to raise the level of HDL, or "good" cholesterol, the company said, sending its shares plunging more than 10 percent.

  • Regulatory "Risky Business" for Pharma & Biotech Monday, 28 Apr 2008 | 11:56 AM ET
    Risky Business

    It's a big day for pipeline progress...or not. Late Friday, Merck and Schering-Plough announced that the Food and Drug Administration won't approve their combo Claritin-Singulair combo pill for allergies.

  • Wyeth Profit Slips, but Tops Wall Street Estimates Tuesday, 22 Apr 2008 | 7:22 AM ET

    Wyeth Tuesday said its first-quarter net profit fell slightly, hurt by the sudden launch early this year of a generic form of its Protonix ulcer drug, but surprisingly strong sales enabled the company to beat Wall Street profit forecasts.

  • Abbott Profit Rises, Boosted by Prescriptions Wednesday, 16 Apr 2008 | 7:51 AM ET

    Abbott Laboratories said Wednesday first-quarter earnings increased 34 percent on higher sales of its prescription drugs and medical devices and favorable foreign exchange factors.

  • Johnson & Johnson's Earnings And Its Very "Taxing" Day Tuesday, 15 Apr 2008 | 3:56 PM ET
    Johnson & Johnson

    Dow component and healthcare conglomerate (drugs, consumer products, medical devices) Johnson & Johnson beat and boosted. That's Wall Street jargon for earnings coming in higher than expectations and the guidance for the rest of the year being raised. So, why did the stock go down?

  • The Week:  Saving the Worst For Last Saturday, 12 Apr 2008 | 7:31 AM ET
    Stocks down

    A steady stream of downbeat news seemed to leave the market unmoved for most of the week -- until the bluest of the blue chips, General Electric, posted first-quarter earnings that missed Wall Street expectations by seven cents per share, and lowered its full-year guidance.  

  • Week Ahead: Challenging -- At The Least Friday, 11 Apr 2008 | 7:34 PM ET

    A double helping of economic data and first-quarter earnings reports will flood the zone next week, but it's the corporate earnings that will drive stocks and give a better picture of where the economy is going. If GE's bombshell earnings miss is an indicator, the news will be as nasty as traders expect.

  • Japan's Takeda to Buy Millennium Pharma Thursday, 10 Apr 2008 | 6:25 AM ET

    Takeda Pharmaceutical said it would buy U.S. firm Millennium Pharmaceuticals for $8.8 billion to boost its cancer drug business, in the biggest overseas acquisition by a Japanese drug maker.

  • Defensive Stock Picks for a Rebound Monday, 7 Apr 2008 | 1:22 PM ET

    After a rough start, top investment officers are looking for gradual improvement as 2008 goes on.  Harbor Advisory's Jack DeGan is among them, and he won't sugar-coat the current situation.

  • Stocks End on High Note But Quarter Is Sour Monday, 31 Mar 2008 | 5:17 PM ET

    Stocks advanced Monday, led by financials, as the market looked for insight into the second quarter and braced for closing its worst quarter in 5 1/2 years.

  • Financials Lead Rebound; Merck Skids Monday, 31 Mar 2008 | 2:16 PM ET

    Stocks advanced Monday, led by financials, as the market looked for insight into the second quarter and braced for closing its worst quarter in 5 1/2 years.

  • Drug Stock Scorecard: MRK, SGP Losers--Pfizer A Winner Monday, 31 Mar 2008 | 11:35 AM ET

    Who’s the winner and loser in drug stocks today? Schering-Plough down 25 percent (!) and Merck down 16 percent pre-open on a study that showed that the companies cholesterol lowering drugs Vytorin and Zetia were not more effective than less expensive drugs.

  • Market-Moving Murmurs Thursday, 27 Mar 2008 | 6:30 PM ET

    The American College Of Cardiology kicks off its annual meeting in Chicago on Saturday. What’s the trade ahead of this major meeting of heart doctors?

  • J&J, Boston Scientific, Medtronic & Abbott: Stent "Stuff" Thursday, 27 Mar 2008 | 10:50 AM ET
    Heart Stent

    Ahead of the world's biggest gathering of cardiologists in Chicago this weekend, there's a flurry of news about stents--the expensive little wire mesh tubes that prop open clogged arteries. First, the Food and Drug Administration has posted new proposed guidelines for pre-and post-market testing of the controversial devices.

  • Lightning Round: Bear Stearns, Disney, Costco and More Thursday, 6 Mar 2008 | 7:23 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • Lightning Round OT: Allergan and More Thursday, 6 Mar 2008 | 7:23 PM ET

    The Lightning Round is extended in this new CNBC.com exclusive feature.

  • What's an Investor to Do? Recession-Proof Stocks Tuesday, 5 Feb 2008 | 3:35 PM ET

    Investors are worried about a recession again.  So  CNBC asked the experts for some recession-proof stock picks.

  • Medical Device Makers: Healthy Buys Tuesday, 5 Feb 2008 | 3:01 PM ET

    The medical device field has its problems -- but Jan Wald thinks the stocks of medical device makers may be excellent defensive plays in the current market environment. "Valuations of these stocks are pretty low at this point," the Stanford Group managing director told CNBC...

  • Boston Scientific And The "Struggling" Stents Tuesday, 5 Feb 2008 | 10:25 AM ET

    Sales of drug-coated stents, Boston Scientific's most profitable products, came in at the low end of the company's guidance in the fourth quarter. Stents are the fragile little wire mesh cylinders that act like scaffolding to prop open clogged arteries.